In 2022, an RCT published in The New England Journal of Medicine found that the incidence of cancers was higher with tofacitinib compared to tumor necrosis factor (TNF) inhibitors in patients with RA older than 50 years of age and had at least one additional cardiovascular risk factor [31]. This evidence concerns the gene TNF and rheumatoid arthritis.